Published in Mol Cancer Ther on June 26, 2013
Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma. BMC Vet Res (2015) 0.85
Immunohistochemical detection of a potential molecular therapeutic target for canine hemangiosarcoma. J Vet Med Sci (2015) 0.76
Association of Sphingosine-1-phosphate (S1P)/S1P Receptor-1 Pathway with Cell Proliferation and Survival in Canine Hemangiosarcoma. J Vet Intern Med (2015) 0.75
Combined inhibition of MEK and mTOR has a synergic effect on angiosarcoma tumorgrafts. Int J Oncol (2015) 0.75
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem (1994) 14.36
Met, metastasis, motility and more. Nat Rev Mol Cell Biol (2003) 14.30
Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med (1999) 7.97
AN UNIDENTIFIED VIRUS WHICH CAUSES THE RAPID PRODUCTION OF TUMOURS IN MICE. Nature (1964) 6.96
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res (2006) 6.66
Angiosarcoma. Lancet Oncol (2010) 4.34
Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer (2008) 3.23
A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J (2005) 2.71
The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg Med Chem Lett (2008) 2.28
Transcriptional regulation by the MAP kinase signaling cascades. Gene (2003) 2.24
Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer (2013) 2.23
ERK1 and ERK2 mitogen-activated protein kinases affect Ras-dependent cell signaling differentially. J Biol (2006) 2.04
MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema. Am J Pathol (2009) 1.92
KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res (2009) 1.69
Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor. Proc Natl Acad Sci U S A (2004) 1.52
Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions. Genes Chromosomes Cancer (2011) 1.31
Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. Proc Natl Acad Sci U S A (2004) 1.31
The Comparative Oncology Trials Consortium: using spontaneously occurring cancers in dogs to inform the cancer drug development pathway. PLoS Med (2009) 1.28
Gene expression profiling identifies inflammation and angiogenesis as distinguishing features of canine hemangiosarcoma. BMC Cancer (2010) 1.13
The pathology of tumors and other lesions induced in rodents by virus derived from a rat with Moloney leukemia. Cancer Res (1966) 1.13
Cutaneous vascular proliferations. Part III. Malignant neoplasms, other cutaneous neoplasms with significant vascular component, and disorders erroneously considered as vascular neoplasms. J Am Acad Dermatol (1998) 1.05
Activation of Ki-ras gene by point mutation in human liver angiosarcoma associated with vinyl chloride exposure. Mol Carcinog (1991) 1.04
ERK2 drives tumour cell migration in three-dimensional microenvironments by suppressing expression of Rab17 and liprin-β2. J Cell Sci (2012) 1.01
Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: a pattern distinct from other sarcomas with complex genomics. Cancer (2012) 0.99
Sporadic and Thorotrast-induced angiosarcomas of the liver manifest frequent and multiple point mutations in K-ras-2. Lab Invest (1997) 0.98
Moloney murine sarcoma virus 349 induces Kaposi's sarcomalike lesions in Balb/c mice. Am J Pathol (1990) 0.93
Mutation of the PTEN gene in a human hepatic angiosarcoma. Cancer Genet Cytogenet (2007) 0.89
Anthrax lethal toxin inhibits growth of and vascular endothelial growth factor release from endothelial cells expressing the human herpes virus 8 viral G protein coupled receptor. Clin Cancer Res (2007) 0.88
Mutation analysis of K-ras-2 in liver angiosarcoma and adjacent nonneoplastic liver tissue from patients occupationally exposed to vinyl chloride. Environ Mol Mutagen (2002) 0.87
Establishment of canine hemangiosarcoma xenograft models expressing endothelial growth factors, their receptors, and angiogenesis-associated homeobox genes. BMC Cancer (2009) 0.86
SV7, a molecular clone of Moloney murine sarcoma virus 349, transforms vascular endothelial cells. Am J Pathol (1991) 0.81
Vascular neoplasms induced in rodent central nervous system by murine sarcoma viruses. Lab Invest (1983) 0.80
Gene expressions of canine angiopoietin-1 and -2 in normal tissues and spontaneous tumours. Res Vet Sci (2006) 0.79
The role of fibroblast growth factor (FGF) in neoplasms induced by MoMuSV-349. Int J Oncol (1997) 0.76
Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med (2002) 21.28
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature (2010) 14.50
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011) 11.02
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol (2008) 6.11
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet (2011) 5.21
Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nat Med (2006) 4.54
Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med (2004) 3.96
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol (2007) 3.79
Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol (2009) 3.72
Skin immune sentinels in health and disease. Nat Rev Immunol (2009) 3.52
The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J Biol Chem (2007) 3.24
An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell (2011) 2.78
Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med (2004) 2.63
Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res (2010) 2.61
Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol (2011) 2.46
The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation. Cancer Cell (2005) 2.34
Anthrax lethal factor proteolysis and inactivation of MAPK kinase. J Biol Chem (2003) 2.32
Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis. Arch Dermatol (2005) 2.28
Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res (2005) 2.27
HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res (2013) 2.27
Cutaneous angiosarcoma of the scalp: a multidisciplinary approach. Cancer (2003) 2.23
Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest (2007) 2.22
Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res (2008) 2.19
Chordoma: the nonsarcoma primary bone tumor. Oncologist (2007) 2.10
Regulation of endocytosis via the oxygen-sensing pathway. Nat Med (2009) 2.00
Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene (2005) 1.99
Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol (2003) 1.92
Notch1 is an effector of Akt and hypoxia in melanoma development. J Clin Invest (2008) 1.89
Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci U S A (2003) 1.86
Soft tissue sarcomas of adults: state of the translational science. Clin Cancer Res (2003) 1.81
Identification of a novel proinflammatory human skin-homing Vγ9Vδ2 T cell subset with a potential role in psoriasis. J Immunol (2011) 1.79
Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity (2013) 1.77
Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo. Cancer Res (2008) 1.76
Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin Cancer Res (2009) 1.76
Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature. Am J Surg Pathol (2008) 1.70
Clonal persistence and evolution during a decade of recurrent melanoma. J Invest Dermatol (2006) 1.69
Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol (2004) 1.69
MicroRNA profiling of human kidney cancer subtypes. Int J Oncol (2009) 1.68
Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res (2002) 1.67
RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin Cancer Res (2002) 1.67
Medical and pediatric oncology, not adult and pediatric oncology. J Clin Oncol (2005) 1.66
Pulmonary nodule volumetric measurement variability as a function of CT slice thickness and nodule morphology. AJR Am J Roentgenol (2007) 1.65
Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene (2005) 1.63
Cutting edge: A critical functional role for IL-23 in psoriasis. J Immunol (2010) 1.61
A molecular classification of papillary renal cell carcinoma. Cancer Res (2005) 1.60
Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jab1 as a potential target for 8q gain in hepatocellular carcinoma. Carcinogenesis (2005) 1.59
Identification of a lysosomal pathway that modulates glucocorticoid signaling and the inflammatory response. Sci Signal (2011) 1.58
A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res (2002) 1.56
The Wnt co-receptor Lrp6 is required for normal mouse mammary gland development. PLoS One (2009) 1.47
Cracking the cytokine code in psoriasis. Nat Med (2007) 1.47
An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. Nat Biotechnol (2009) 1.47
Phosphorylated FADD induces NF-kappaB, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas. Proc Natl Acad Sci U S A (2005) 1.44
Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. Oncogene (2003) 1.42
Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci U S A (2009) 1.42
Genetic and structural variation in the gastric cancer kinome revealed through targeted deep sequencing. Cancer Res (2010) 1.41
Reduced selenium-binding protein 1 expression is associated with poor outcome in lung adenocarcinomas. J Pathol (2004) 1.41
Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA. Cancer Res (2006) 1.41
Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation. Cancer Res (2008) 1.41
p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas. Mol Cancer Ther (2004) 1.40
Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase. Proc Natl Acad Sci U S A (2002) 1.38
Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol (2009) 1.38
Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J Clin Endocrinol Metab (2008) 1.37
Transendothelial function of human metastatic melanoma cells: role of the microenvironment in cell-fate determination. Cancer Res (2002) 1.36
Anthrax toxin-induced shock in rats is associated with pulmonary edema and hemorrhage. Microb Pathog (2007) 1.36
Active Notch1 confers a transformed phenotype to primary human melanocytes. Cancer Res (2009) 1.36
Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res (2004) 1.35
Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors. Oncologist (2008) 1.34
The E2F3-Oncomir-1 axis is activated in Wilms' tumor. Cancer Res (2008) 1.33
Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). Cancer (2013) 1.32
The Notch ligand Jagged-1 is able to induce maturation of monocyte-derived human dendritic cells. J Immunol (2002) 1.30
Selection of response criteria for clinical trials of sarcoma treatment. Oncologist (2008) 1.30
Cancer survivors in the United States: a review of the literature and a call to action. Int J Med Sci (2012) 1.30
Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat (2005) 1.30
Undifferentiated small round cell sarcoma with t(4;19)(q35;q13.1) CIC-DUX4 fusion: a novel highly aggressive soft tissue tumor with distinctive histopathology. Am J Surg Pathol (2013) 1.29
Identification of frequent cytogenetic aberrations in hepatocellular carcinoma using gene-expression microarray data. Genome Biol (2002) 1.29
Expression and effect of inhibition of the ubiquitin-conjugating enzyme E2C on esophageal adenocarcinoma. Neoplasia (2006) 1.28
When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst (2012) 1.28
BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin. Mol Cancer Ther (2005) 1.27
Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation. Clin Cancer Res (2006) 1.27
Sensitizing anthrax lethal toxin-resistant macrophages to lethal toxin-induced killing by tumor necrosis factor-alpha. J Biol Chem (2002) 1.26
Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma. Cancer Res (2007) 1.26
Inhibition of PAX3 by TGF-beta modulates melanocyte viability. Mol Cell (2008) 1.26
Notch-independent regulation of Hes-1 expression by c-Jun N-terminal kinase signaling in human endothelial cells. Lab Invest (2006) 1.24
Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and β-catenin. Am J Pathol (2012) 1.23
Role of IFI 16, a member of the interferon-inducible p200-protein family, in prostate epithelial cellular senescence. Oncogene (2003) 1.23
Cluster analysis of immunohistochemical profiles in synovial sarcoma, malignant peripheral nerve sheath tumor, and Ewing sarcoma. Mod Pathol (2006) 1.23
CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma. Cancer Res (2013) 1.23
CYP24A1 is an independent prognostic marker of survival in patients with lung adenocarcinoma. Clin Cancer Res (2010) 1.23
Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res (2010) 1.23
Conservation of genetic alterations in recurrent melanoma supports the melanoma stem cell hypothesis. Cancer Res (2008) 1.22
Focal adhesion kinase promotes the aggressive melanoma phenotype. Cancer Res (2005) 1.22
Notch signaling regulates mouse and human Th17 differentiation. J Immunol (2011) 1.21